Download Curriculum Vitae - University of Michigan School of Public

INACTIVATION OF SAG/RBX2/ROC2 E3 UBIQUITIN LIGASE SUPPRESSES KRASG12D-DRIVEN
LUNG TUMORIGENESIS UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER •
BOSTATISTICS UNIT • M2541 • 1420 WASHINGTON HEIGHTS • ANN ARBOR, MI 48109-5473
PHONE (734) 763-6898 • FAX (734) 936-4540 • E-MAIL [email protected]
LILI ZHAO
EDUCATION
September 2003 – December 2006
University of Iowa, Iowa City, IA
Ph.D., Statistics
 Dissertation Title: “Bayesian Sequential Analysis for Phase II Clinical Trials”
September 2001 – September 2003
University of Iowa, Iowa City, IA
M.S., Statistics
July 1995 – July 1999
The Capital University of Economics and Business, Beijing, China
B.S., Marketing and Economics
PROFESSIONAL EXPERIENCE
Research Assistant Professor
March 2014 – present
Biostatistics Department, University of Michigan, Ann Arbor, Michigan
Research Investigator
September 2011 – March 2014
Biostatistics Department, University of Michigan, Ann Arbor, Michigan
Statistician Lead
December 2007 – September 2011
Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan
Senior Statistician
September 2006 – December 2007
Becton, Dickinson and Company, Baltimore, MD
Last Updated: April 30, 2015
Page 1
EXTERNAL PROFESSIONAL SERVICE
Manuscript Referee for:
Clinical Cancer Research
Contemporary Clinical Trials
Statistics in Medicine
Statistical Modeling
Journal of Clinical Oncology
Biometrical Journal
Biometrics
Journal of the American Statistical Association
BMC Pediatrics
Journal of Applied Statistics
Annals of Human Genetics
Future Science
Statistical Applications in Genetics and Molecular Biology
Computer Methods and Programs in Biomedicine
Pharmaceutical Statistics
PLOS Computational Biology
International Statistical Review
Book Reviewer: “Bayesian Methods in Epidemiology” by Lyle D. Broemeling,
Chapman & Hall/CRC, 2014
Reviewer: NSA-AMS grant, 2014
PRESENTATIONS
Contributed Presentation, “Bayesian Sequential Analysis for Survival Data.” August
2006, JSM Annual Conference.
Invited Presentation, “Bayesian Hierarchical Changepoint Methods in Modeling the
Tumor Growth Profiles in Xenograft Experiments.” October 2009, Bowling Green
State University.
Invited Presentation, “Bayesian Decision Sequential Analysis with Survival Endpoint
in Phase II Clinical Trials.” January 2010, MD Anderson Cancer Center Bayesian
Biostatistics Conference.
Invited Presentation, “Bayesian two-stage design in Phase II clinical trials with timeto-event endpoint: A simulation-based decision-theoretic approach.” June 2011, Third
IWSM Conference, Stanford University.
Invited Presentation, “Bayesian two-stage design in Phase II clinical trials with timeto-event endpoint: A simulation-based decision-theoretic approach.” January 2012, MD
Anderson Cancer Center Bayesian Biostatistics Conference.
Last Updated: April 30, 2015
Page 2
Invited Presentation, “Bayesian Hierarchical Changepoint Methods in Modeling the
Tumor Growth Profiles in Xenograft Experiments.” June 2013, University of Chinese
Academy of Sciences, School of Mathematical Sciences.
Contributed Presentation, “Bayesian two-stage design in Phase II clinical trials with
time-to-event endpoint: A simulation-based decision-theoretic approach.” July 2013,
IMS-China international Conference.
Invited Presentation, “Bayesian two-stage design in Phase II clinical trials with timeto-event endpoint: A simulation-based decision-theoretic approach.” June 2014, Joint
Applied Statistics Symposium of International Chinese Statistical Association and
Korean International Statistical Society.
Contributed Presentation, “Evaluation of treatment efficacy using a Bayesian mixture
piecewise linear model of longitudinal biomarkers.” August 2015, JSM Annual
Conference
PROFESSIONAL MEMBERSHIPS
American Statistical Association, April 2006 to present
International Society for Bayesian Analysis, July 2011 to present
PEER-REVIEWED PUBLICATIONS
Publications (peer-reviewed; published or accepted)
2014-2015
Zhao L, Feng D, Neelon B and Buyse M. Evaluation of treatment efficacy using a
Bayesian mixture piecewise linear model of longitudinal biomarkers. Statistics in
Medicine, 34(10): 1733-1746, 2015
Zhao L, Shi J, Shearon TH, and Li Y. A Dirichlet process mixture model for survival
outcome data: assessing nationwide kidney transplant centers. Statistics in Medicine,
34(8): 1404-1416, 2015
Nadal E, Chen G, Prensner JR, Shiratsuchi H, Sam C, Zhao L, Kalemkerian GP,
Brenner D, Lin J, Reddy RM, Chang AC, Capellà G, Cardenal F, Beer DG and
Ramnath N. KRAS-G12C mutation is associated with poor outcome in surgically
resected lung adenocarcinoma. Journal of Thoracic Oncology, 9(10): 1513-1522, 2014
Jiang Y, Djuric Z, Sen A, Ren J, Kuklev D, Waters I, Zhao L, Uhlson CL, Hong YH,
Murphy RC, Normolle DP, Smith WL and Brenner DE. Biomarker for personalizing
omega-3 fatty acid dosing. Cancer Prev Res, 7(10):1011-1022, 2014
Arps DP, Jorns JM, Zhao L, Bensenhaver J, Kleer CG and Pang JC. Re-excision rates
of invasive ductal carcinoma with lobular features compared with invasive ductal
carcinomas and invasive lobular carcinomas of the breast. Annals of Surgical
Oncology, 21:4152–4158, 2014
Last Updated: April 30, 2015
Page 3
Brown NA, Rolland DC, McHugh JB, Weigelin HC, Zhao L, Lim MS, ElenitobaJohnson KS, Betz BL. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Clin Cancer Res, 20(21): 5517–26, 2014
Kantola S, Virani N, Haus C, Hipp J, Zhao L and Jing X. Prospective Evaluation of
Impact of Using The Bethesda System for Reporting Thyroid Cytopathology: An
Institutional Experience. Journal of the American Society of Cytopathology, 4: 25-29,
2015
Karnak D, Engelke C, Parsels LA, Kausar T. Wei D, Robertson J, Marsh K, Davis M,
Zhao L, Maybaum J, Lawrence TS and Morgan MA. Combined inhibition of Wee1
and PARP1/2 for radiosensitization in pancreatic cancer. Clinical Cancer Research,
Published OnlineFirst on August 12, 2014
Xie CM, Wei D, Zhao L, Marchetto S, Mei L, Borg JP, and Sun Y. Erbin is a novel
substrate of Sag-βTrCP E3 ligase that regulates KrasG12D-induced skin
tumorigenesis. J. Cell Biol, in press.
ACTIVATING FG 2013-2014
Zhao L, Feng D, Bellile E and Taylor JMG. Bayesian Random Threshold Estimation
in a Cox Proportional Hazards Cure Model. Statistics in Medicine, 33(4):650-661, 2014
Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe A, Chung F, Bailey N, Schrader A,
Li B, Li J, Ozel A, Betz B, Miranda R, Medeiros LJ, Zhao L Herling M, Lim MS,
Elenitoba-Johnson KS. Integrated Genomic Sequencing Reveals Mutational Landscape
of T-cell Prolymphocytic Leukemia. Blood, 124(9):1460-72, 2014.
Ilona I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E et al. IL-22(+)CD4(+) T cells
promote colorectal cancer stemness via STAT3 transcription factor activation and
induction of the methyltransferase DOT1L. Immunity, 40(5):772-84, 2014.
Lu JC, Connelly JA, Zhao L et al. Strain measurement by cardiovascular magnetic
resonance in pediatric cancer survivors: Validation of feature tracking against harmonic
phase imaging. Pediatric Radiology, 44: 1070-1076, 2014
Li H, Tan M, Jia L, Wei D, Zhao Y. Chen G. Xu J. Zhao L et al. Inactivation of
SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven tumorigenesis. The Journal
of Clinical Investigation, 124(2):835-846, 2014
Cui T, Kryczek I, Zhao L, Zhao E, Kuick R, Roh M et al. Myeloid-derived
suppressor cell (MDSC), immune suppression, microRNA, CtBP2, ovarian cancer and
survival. Immunity, 39(3): 611-621, 2013 Engelke CG, Parsels LA, Qian Y, Zhang Q, Karnak D, Robertson JR, Wei D, Davis MA,
Parsels JD, Tanska DM, Zhao L et al. Sensitization of pancreatic cancer to
chemoradiation by the Chk1 inhibitor, MK8776. Clin Cancer Res, 19(16):4412-21,
2013.
Last Updated: April 30, 2015
Page 4
VanderVeen N, Paran C, Krasinkiewicz J, Zhao L et al. Effectiveness and preclinical
safety profile of doxycycline to be used “off-label” to induce therapeutic transgene
expression in a Phase I clinical trial for glioma. Hum Gene Ther Clin Dev, 24(3):11626,2013
Hoodin F, Zhao L, Carey J, Levine JE, Kitko C. Impact of Psychological Screening on
Routine Outpatient Care of Hematopoietic Cell Transplantation Survivors Biology of
Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation,
19(10):1493-1497,2013
Wei D, Parsels LA, Karnak D, Davis MA, Parsels JD, Zhao L et al. Inhibition of
protein phosphatase 2A radiosensitizes pancreatic cancers by modulating
CDC25C/CDK1 and homologous recombination repair. Clin Cancer Res, 19(16):442232, 2013.
2012-2013
Sheetz KH, Zhao L, Holcombe SA, Wang SC, Reddy RM, Lin MB et al. Decreased
core muscle size is associated with worse patient survival following esophagectomy for
cancer. Dis Esophagus, 26(7):716-22, 2013
Jorns JM, Healy P and Zhao L. Review of Estrogen Receptor, Progesterone Receptor,
and HER-2/neu Immunohistochemistry Impacts on Treatment for a Small Subset of
Breast Cancer Patients Transferring Care to Another Institution. Arch Pathol Lab Med,
137(11):1660-3, 2013
Arps DP, Healy P, Zhao L, Kleer CG and Pang JC. Invasive ductal carcinoma with
lobular features: a comparison study to invasive ductal and invasive lobular carcinomas
of the breast. Breast Cancer Res Treat, 138(3):719-26, 2013
Zhao L, Taylor JMG, Schuetze SM. Bayesian decision theoretic two-stage design in
Phase II clinical trials with survival endpoints, Statistics in Medicine 31(17):18041820, 2012
Venkatesha VA, Parsels LA, Parsels JD, Zhao L, Zabludoff SD, Simeone D et al.
Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.
Neoplasia, 14:519-25, 2012.
Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG , Chiang MY et al. Wholegenome sequencing identifies recurrent somatic NOTCH2 mutations in splenic
marginal zone lymphoma. J Exp Med. 209(9) 1553-65, 2012
Zhao L, Banerjee M. Bayesian piecewise mixture model for racial disparity in prostate
cancer. Computational Statistics and Data Analysis 56(2):362-369, 2012
Schuetze SM, Zhao L, Chugh R et al. Results of a phase II study of sirolimus and
cyclophosphamide in patients with advanced sarcoma. Eur J Cancer 48(9):1347-53,
2012
Teman N, Silski L, Zhao L, Kober M, Urba SC, Orringer MB et al. Thromboembolic
Last Updated: April 30, 2015
Page 5
Events During Neoadjuvant Treatment of Esophageal Cancer Delay Time to Surgery.
Ann Thorac Surg 94(4):1118-25, 2012
Kim SH, Chen G, King AN, Jeon CK, Christensen PJ, Zhao L et al. Characterization
of Vitamin D Receptor (VDR) in Lung Adenocarcinama. Lung Cancer 2012.
Wei DP, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS et al. Radiosensitization of
human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating
enzyme inhibitor. Cancer Res. 72(1): 282-93, 2011.
Vance S, Liu E, Zhao L, Parsels J, Parsels L, Brown J et al. Selective
radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of
Chk1 and PARP1. Cell Cycle, 10:4321-29, 2011.
Zhao L, Lee J, Mody, R and Braun TM. The Superiority of the Time-to-Event
Continual Reassessment Method to the Rolling Six Design in Pediatric Phase I Cancer
Trials. Clinical Trials 8(4):361-369, 2011
Ray D, Ahsan A, Helman A, Chen G, Hegde A, Gurjar SR, Zhao L, Kiyokawa H, Beer
DG, Lawrence TS, Nyati MK. Regulation of EGFR protein stability by the HECT-type
ubiquitin ligase MURF2. Neoplasia,13(7):570-8, 2011
Parsels L, Qian Y, Tanska D, Gross M, Zhao L, Hassan M, et al. Chk1
phosphorylation as a pharmacodynamic biomarker of Chk1 inhibition. Clin Cancer
Res, 17:3706-15, 2011.
Bhojani MS, Nyati MK, Zhao L, Normolle, DP, Ross BD, Lawrence TS, Rehemtulla
A. Molecular Imaging of Akt Enables Early Prediction of Response to Molecular
Targeted Therapy. Transl Oncol 4(3): 122-125, 2011.
Zhao L, Morgan MA, Parsels LA, et al. Response to Letter from Bassukas. Clinical
Cancer Research 17: 4613, 2011
Lao CD, Johnson T, Sondak VK, Lowe L, Kim DS, Zhao L, Naftanel M, Olsen S,
Brenner DE. Feasibility of serial biopsies of large dysplastic nevi as a melanoma
chemoprevention model. J Am Acad Dermato 64(6):1188-90,2011
Davis SJ, Zhao L, Chang A and Orringer M. Refractory cervical esophagogastric
anastomotic strictures: management and outcomes. Journal of Thoracic and
Cardiovascular Surgery 141:444-448, 2011
Chen G, Kim SH, King A, Zhao L, et.al. CYP24A1 Is an Independent Prognostic
Marker of Survival in Patients with Lung Adenocarcinoma. Clinical Cancer Research
17: 817-826, 2011
Tan L, Kwok RP, Shukla A, Kshirsagar M, Zhao L, et al. Trichostatin a restores Apaf1 function in chemoresistant ovarian cancer cells. Cancer 4: 784-794, 2011
Zhao L, Morgan MA, Parsels LA, et al. Bayesian Hierachical changepoint methods in
modeling the tumor growth profiles in xenograft experiments. Clinical Cancer
Research 17(5): 1-7, 2010
Last Updated: April 30, 2015
Page 6
Morgan MA, Parsles LA, Parsels JD, Davis MA, Hassan MC, Arumugarajah S,
Hylander-Gans L, Morosini D, Zhao L, et al. Mechanism of radiosensitization by the
Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of
homologous recombinational DNA repair. Cancer Research 70(12):4972-4981, 2010
Jing X, Roh, M, Knoepp S, Zhao L and Michael C. Follicular Lesion of Undetermined
Significance and Identifying Predictive Features for Neoplasia. Diagnostic
Cytopathology 2010
Ning W. and Zhao L. A moment-based test for the mixture distributions with small
sample sizes and its application. Far East Journal of Theoretical Statistics. 33(1): 2329, 2010
Anderson M, Brenner D, Scheiman J, Simeone D, Singh N, Sikora M, Zhao L,
Mertens A. Reliable gene expression measurements from endoscopic fine needle
aspirates of pancreatic tumors: effect of amplicon length and quality assessment.
Journal of Molecular Diagnostics 12(5): 566-575, 2010
Zhao L, Woodworth G. Bayesian Decision-Theoretic Group Sequential Analysis with
Survival Endpoints. Statistics in Medicine 28:1339–1352, 2009
Stoffel E, Turgeon D, Stockwell D, Zhao L, et al. Missed Adenomas during
Colonoscopic Surveillance in Individuals with Lynch Syndrome (Hereditary
Nonpolyposis Colorectal Cancer). Cancer Prevention Research 1, 470-475, 2008.
Moon J, Kuehn D, Chen G, Zhao L. Induced Velopharyngeal Fatigue Effects in
Speakers with Repaired Palatal Clefts. The Cleft Palate-Craniofacial Journal 44, 251260, 2007.
Last Updated: April 30, 2015
Page 7